Jin Sun Choi, Ji-Young Kim, Min-Joo Ahn, Seungtaek Song, Doyoun Kim, Sung Hoon Choi, Ye-Soo Park, Tae-Jong Kim, Sungsin Jo, Tae-Hwan Kim, Seung Cheol Shim
{"title":"塞来昔布是唯一的非甾体类抗炎药，可抑制脊柱关节炎的骨质进展。","authors":"Jin Sun Choi, Ji-Young Kim, Min-Joo Ahn, Seungtaek Song, Doyoun Kim, Sung Hoon Choi, Ye-Soo Park, Tae-Jong Kim, Sungsin Jo, Tae-Hwan Kim, Seung Cheol Shim","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>[Erratum to: BMB Reports 2025; 58(3): 140-145, PMID: 39757202, PMCID: PMC11955732] The BMB Reports would like to issue a correction to an article published in BMB Rep. 58(3): 140-145, titled \"Celecoxib is the only nonsteroidal anti-inflammatory drug to inhibit bone progression in spondyloarthritis\". The original acknowledgment contained incorrect grant information. This has now been corrected at the authors' request as follows: This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (NRF-2016R1 A6A3A11930589, NRF-2016R1A6A3A11934500, NRF-2016 R1D1A3 B03931646, NRF-2019R1I1A1A01057738, NRF-2019R1l1A3A01060016, NRF-2019R1l1A1A01060116, and RS-2023-00248058). It was also supported by the Chungnam National University Hospital Research Fund 2021 (2021-CF-033). Specifically, the grant number has been updated from 2016 (2016-CF-003) to 2021 (2021-CF-033). The authors apologize for any inconvenience or confusion this error may have caused. The ACKNOWLEDGEMENTS section in the original PDF version has been updated accordingly.</p>","PeriodicalId":9010,"journal":{"name":"BMB Reports","volume":"58 4","pages":"190"},"PeriodicalIF":2.9000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041925/pdf/","citationCount":"0","resultStr":"{\"title\":\"Erratum to: Celecoxib is the only nonsteroidal anti-inflammatory drug to inhibit bone progression in spondyloarthritis.\",\"authors\":\"Jin Sun Choi, Ji-Young Kim, Min-Joo Ahn, Seungtaek Song, Doyoun Kim, Sung Hoon Choi, Ye-Soo Park, Tae-Jong Kim, Sungsin Jo, Tae-Hwan Kim, Seung Cheol Shim\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>[Erratum to: BMB Reports 2025; 58(3): 140-145, PMID: 39757202, PMCID: PMC11955732] The BMB Reports would like to issue a correction to an article published in BMB Rep. 58(3): 140-145, titled \\\"Celecoxib is the only nonsteroidal anti-inflammatory drug to inhibit bone progression in spondyloarthritis\\\". The original acknowledgment contained incorrect grant information. This has now been corrected at the authors' request as follows: This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (NRF-2016R1 A6A3A11930589, NRF-2016R1A6A3A11934500, NRF-2016 R1D1A3 B03931646, NRF-2019R1I1A1A01057738, NRF-2019R1l1A3A01060016, NRF-2019R1l1A1A01060116, and RS-2023-00248058). It was also supported by the Chungnam National University Hospital Research Fund 2021 (2021-CF-033). Specifically, the grant number has been updated from 2016 (2016-CF-003) to 2021 (2021-CF-033). The authors apologize for any inconvenience or confusion this error may have caused. The ACKNOWLEDGEMENTS section in the original PDF version has been updated accordingly.</p>\",\"PeriodicalId\":9010,\"journal\":{\"name\":\"BMB Reports\",\"volume\":\"58 4\",\"pages\":\"190\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041925/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMB Reports\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"\",\"RegionNum\":3,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMB Reports","FirstCategoryId":"99","ListUrlMain":"","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Erratum to: Celecoxib is the only nonsteroidal anti-inflammatory drug to inhibit bone progression in spondyloarthritis.
[Erratum to: BMB Reports 2025; 58(3): 140-145, PMID: 39757202, PMCID: PMC11955732] The BMB Reports would like to issue a correction to an article published in BMB Rep. 58(3): 140-145, titled "Celecoxib is the only nonsteroidal anti-inflammatory drug to inhibit bone progression in spondyloarthritis". The original acknowledgment contained incorrect grant information. This has now been corrected at the authors' request as follows: This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (NRF-2016R1 A6A3A11930589, NRF-2016R1A6A3A11934500, NRF-2016 R1D1A3 B03931646, NRF-2019R1I1A1A01057738, NRF-2019R1l1A3A01060016, NRF-2019R1l1A1A01060116, and RS-2023-00248058). It was also supported by the Chungnam National University Hospital Research Fund 2021 (2021-CF-033). Specifically, the grant number has been updated from 2016 (2016-CF-003) to 2021 (2021-CF-033). The authors apologize for any inconvenience or confusion this error may have caused. The ACKNOWLEDGEMENTS section in the original PDF version has been updated accordingly.
期刊介绍：
The BMB Reports (BMB Rep, established in 1968) is published at the end of every month by Korean Society for Biochemistry and Molecular Biology. Copyright is reserved by the Society. The journal publishes short articles and mini reviews. We expect that the BMB Reports will deliver the new scientific findings and knowledge to our readers in fast and timely manner.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
